382 related articles for article (PubMed ID: 29688330)
1. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
[TBL] [Abstract][Full Text] [Related]
2. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
3. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
[TBL] [Abstract][Full Text] [Related]
5. Activation of invariant natural killer T cells in regional lymph nodes as new antigen-specific immunotherapy via induction of interleukin-21 and interferon-γ.
Sakurai T; Inamine A; Iinuma T; Funakoshi U; Yonekura S; Sakurai D; Hanazawa T; Nakayama T; Ishii Y; Okamoto Y
Clin Exp Immunol; 2014 Oct; 178(1):65-74. PubMed ID: 24943738
[TBL] [Abstract][Full Text] [Related]
6. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
7. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
[TBL] [Abstract][Full Text] [Related]
8. An in silico approach for modelling T-helper polarizing iNKT cell agonists.
De Spiegeleer A; Wynendaele E; Vandekerckhove M; Stalmans S; Boucart M; Van Den Noortgate N; Venken K; Van Calenbergh S; Aspeslagh S; Elewaut D
PLoS One; 2014; 9(1):e87000. PubMed ID: 24498010
[TBL] [Abstract][Full Text] [Related]
9. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
Front Immunol; 2019; 10():2355. PubMed ID: 31649670
[TBL] [Abstract][Full Text] [Related]
10. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.
Wojno J; Jukes JP; Ghadbane H; Shepherd D; Besra GS; Cerundolo V; Cox LR
ACS Chem Biol; 2012 May; 7(5):847-55. PubMed ID: 22324848
[TBL] [Abstract][Full Text] [Related]
11. Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15.
Hsu CY; Chueh YS; Kuo ML; Lee PT; Hsiao HS; Huang JL; Lin SJ
PLoS One; 2021; 16(12):e0261727. PubMed ID: 34936686
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological activities of amino acids functionalized α-GalCer analogues.
Ma W; Bi J; Zhao C; Zhang Z; Liu T; Zhang G
Bioorg Med Chem; 2020 Jan; 28(1):115141. PubMed ID: 31786009
[TBL] [Abstract][Full Text] [Related]
13. Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells.
Fallarini S; Paoletti T; Panza L; Lombardi G
Biochem Pharmacol; 2008 Sep; 76(6):738-50. PubMed ID: 18671950
[TBL] [Abstract][Full Text] [Related]
14. Invariant NKT cells facilitate cytotoxic T-cell activation via direct recognition of CD1d on T cells.
Qin Y; Oh S; Lim S; Shin JH; Yoon MS; Park SH
Exp Mol Med; 2019 Oct; 51(10):1-9. PubMed ID: 31653827
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
16. Activation of invariant natural killer T cells impedes liver regeneration by way of both IFN-γ- and IL-4-dependent mechanisms.
Yin S; Wang H; Bertola A; Feng D; Xu MJ; Wang Y; Gao B
Hepatology; 2014 Oct; 60(4):1356-66. PubMed ID: 24623351
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
Berkers CR; Ovaa H
Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
[TBL] [Abstract][Full Text] [Related]
18. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
[TBL] [Abstract][Full Text] [Related]
19. Differential dendritic cell-mediated activation and functions of invariant NKT-cell subsets in oral cancer.
Singh AK; Gaur P; Shukla NK; Das SN
Oral Dis; 2015 Jan; 21(1):e105-13. PubMed ID: 24654917
[TBL] [Abstract][Full Text] [Related]
20. Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis.
Yoshiga Y; Goto D; Segawa S; Horikoshi M; Hayashi T; Matsumoto I; Ito S; Taniguchi M; Sumida T
Clin Exp Immunol; 2011 May; 164(2):236-47. PubMed ID: 21391989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
